Carl Zeiss Meditec AG Financial Results FY 2024/25 | Margin Outlook & Strategy Update

Carl Zeiss Meditec AG FY 2024/25: Key TakeawaysCarl Zeiss Meditec FY 2024/25 Financial ResultsStrategic Realignment Drives Resilient Growth and Sets the Stage for Margin ExpansionIn its FY 2024/25 financial results presentation, Carl Zeiss Meditec Group demonstrates that it remains firmly positioned in structurally attractive global healthcare technology markets, while simultaneously acknowledging the need for sharper execution and strategic focus to unlock its full earnings potential. The year was marked by solid revenue growth, robust order intake, and the first tangible effects of a broader strategic realignment aimed at restoring profitability momentum over the medium term.Solid Top-Line Growth and Strong Order MomentumCarl Zeiss Meditec delivered reported revenue of approximately €2.23 billion in FY 2024/25, reflecting solid growth compared with the prior year. On a foreign-exchange adjusted basis, revenue growth was clearly positive, supported by a combination of organic demand and the full-year consolidation of DORC in Ophthalmology. Order intake developed particularly strongly, increasing at a double-digit rate year-on-year on a constant-currency basis, resulting in a healthy order backlog that underpins revenue visibility into the new fiscal year.Growth was broad-based across regions. EMEA and the Americas showed especially strong momentum, while Asia-Pacific continued to contribute meaningfully despite a more challenging environment in China. Importantly for investors, order entry growth outpaced revenue growth, signalling ongoing demand strength across key product categories and geographies.Earnings: Stable EBITA Amid Headwinds, Adjusted Margin ImprovementOn the profitability side, EBITA increased slightly year-on-year, landing broadly in line with management guidance. Reported EBITA margin declined modestly compared with the prior year, reflecting a combination of adverse foreign exchange effects, US tariff-related headwinds, and a prior-year one-off gain related to the Topcon settlement. On an adjusted basis, however, EBITA margin improved, underlining the underlying progress in operating efficiency.A key positive driver was the reduction in underlying operating expenses excluding DORC effects, particularly through lower R&D spending and reduced integration costs. This demonstrates early discipline in capital allocation and cost management, even as the company continues to invest selectively in future growth areas.Segment Performance: Ophthalmology Strengths Offsets Microsurgery TransitionOphthalmology remained the group’s core earnings pillar. Consumables, premium intraocular lenses, and the full-year contribution from DORC drove revenue growth in this segment. Margin expansion in Ophthalmology was supported by operating leverage and improved cost discipline, reinforcing the segment’s role as the primary value driver within the portfolio.Microsurgery, while showing a recovery in revenue momentum toward year-end, continued to face margin pressure due to product mix effects, delayed ramp-up of new systems, and ongoing investments in commercialization and market development. Management clearly positioned this as a transitional phase, with expectations of improved profitability as new products scale and operational measures take effect.....▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.